Direct-to-consumer testing allows patients to order tests directly from a laboratory without going through their healthcare provider, and often at lower cost.
The anticipated growth is attributed to aging populations, rising demand for early disease detection and diagnosis, and the increasing prevalence of lifestyle-associated and infectious diseases such as obesity, hypertension, diabetes, cancer and STDs.
Genetic testing dominated the direct-to-consumer market in 2020, according to the report, and it’s predicted to continue doing so through 2031.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
